Oral glycoprotein IIb/IIIa antagonists: New insights from the SYMPHONY trial

Journal of Thrombosis and Thrombolysis

Volumn 10, Issue 2, 2000, Pages 111-119

  McGuire, D K ^a   Newby, L K ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Coronary artery disease; Glycoprotein IIb IIIa inhibitors; Platelet aggregation inhibitors; Platelets; Secondary prevention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LEFRADAFIBAN; LOTRAFIBAN; ORBOFIBAN; SIBRAFIBAN; TIROFIBAN; XEMILOFIBAN;

BLEEDING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE CALCULATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; FATALITY; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; THROMBOSIS;

EID: 0033754471     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018782708070     Document Type: Review

References (25)

1. Insights into the pathogenesis of acute ischemic syndromes
2. A macro and micro view of coronary vascular insult in ischemic heart disease
3. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
4. Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use?
5. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk angioplasty
6. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
7. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
8. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
9. The effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
10. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
11. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
12. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
13. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI-12 trial
14. Sustained platelet GP IIb/IIIa blockade with oral orbofiban: Interim pharmacodynamic results of the SOAR study
15. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multicenter, placebo-controlled, randomized trial
16. Fibrinogen Receptor Occupancy Studies (FROST): Safety and preliminary efficacy of a one month treatment with lefradafiban in patients with unstable angina
17. Dose-finding, safety, and tolerability of an oral glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease
18. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial
19. AHJ at the meetings: Highlights from the American College of Cardiology 48th Annual Scientific Sessions: March 7 to 10, 1999
20. Orbofiban in patients with unstable coronary syndromes (OPUS, TIMI-16) preliminary results
21. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary sYndromes (SYMPHONY) trial
22. The Evaluation of Xemilofiban in Controlling Thrombotic Events (EXCITE) trial: 30-day and six-month results
23. Reversible conformational changes induced in glycoprotein IIb/IIIa by a potent and selective peptidomimetic inhibitor
24. 3 on platelets
25. Troponin-I identifies patients with unstable coronary artery disease who benefit from long-term oral glycoprotein IIb/IIIa inhibition: The FROST study